Seven Anti-Aging Drugs Entered Clinical Trials. The Two That Worked Weren't Tested on Humans.

One hundred and fifty adults. Forty-eight weeks. Two dose arms. The PEARL trial was supposed to be the moment rapamycin proved itself in humans.

It didn't.

Not because rapamycin failed. Because the compounding pharmacy did. A parallel bioavailability study published on medRxiv revealed that the compounded rapamycin capsules used in PEARL delivered threefold less drug per milligram than generic sirolimus. The 5 mg arm was effectively getting 1.5 mg. The 10 mg arm was getting 3 mg. The entire trial was under-dosed by a factor of three, and nobody realized until the data started coming back flat.

Except it wasn't entirely flat. Women in the 10 mg group — the one actually delivering a pharmacologically meaningful dose — showed statistically significant gains in lean muscle mass. A signal buried under a compounding error.

The Scorecard

Here is every serious anti-aging drug trial as of March 2026, scored honestly.

Drug	Trial	Endpoint	Status	Verdict
Rapamycin	PEARL (NCT04488601)	Aging biomarkers	Completed 2025	⚠️ Undermined by 3× bioavailability deficit
Rapamycin	TRIAD (Dog Aging Project)	Canine lifespan + cardiac	Enrolling (580 target)	✅ Cardiac improvement confirmed in prior phases
Metformin	TAME (NCT02432287)	Multi-disease composite	Still recruiting	⏳ 5+ years, no primary data yet
UBX1325 (senolytic)	BEHOLD Phase 2	Diabetic macular edema	Published in NEJM Evidence	✅ Disease-modifying vision improvement
D+Q (senolytics)	Pilot (NCT02848131)	Senescent cells in DKD	Phase 1 complete	✅ Cleared senescent cells; tiny n (14)
LOY-002	Loyal (canine)	Lifespan extension	FDA RXE accepted Feb 2025	✅ First-ever lifespan-as-label-claim signal
LOY-001	Loyal (large breed canine)	IGF-1 reduction, lifespan	FDA RXE accepted 2023	✅ IGF-1 pathway validated

Count the green checkmarks. Two dog pills. One eye injection. One pilot study with fourteen patients. Zero completed large-scale human trials with positive primary endpoints on systemic aging.

PEARL: How a Pharmacy Destroyed a $10M Trial

The PEARL study, led by researchers at AgelessRx and registered at ClinicalTrials.gov under NCT04488601, enrolled 150 healthy adults aged 50–85 and randomized them to 5 mg/week rapamycin, 10 mg/week rapamycin, or placebo for 48 weeks. The trial measured physical function, body composition via DEXA scans, metabolic biomarkers (A1c, insulin, lipids), inflammatory markers (CRP), gut microbiome composition, and cognitive function.

The primary results were underwhelming. No significant changes in most aging biomarkers. No meaningful shifts in inflammatory markers. No cognitive signal.

Then came the bioavailability bombshell. Compounded rapamycin degrades in gastric acid. The capsules the participants swallowed for a year were losing two-thirds of their payload before reaching the bloodstream. What was designed as a Phase 2 dose-ranging study accidentally became a study of sub-therapeutic dosing.

The lean muscle finding in women is worth tracking. Professor David Glass's lab had independently shown that intermittent mTOR inhibition with a rapalog reduced anabolic resistance in aging muscle, preserving the ability to build lean tissue. PEARL's female 10 mg cohort, even under-dosed, moved in exactly this direction. It's not proof. It's the kind of signal that justifies a properly dosed follow-up.

The Dogs Are Ahead of Us

On February 26, 2025, the FDA's Center for Veterinary Medicine accepted Loyal's reasonable expectation of effectiveness (RXE) package for LOY-002. A daily pill for senior dogs targeting age-associated metabolic dysfunction — insulin resistance, visceral fat accumulation, chronic inflammation.

This was historic. Not for the drug. For the claim.

Lifespan extension has never been an approvable indication for any drug in any major species under any regulatory framework in the United States. The FDA's acceptance of LOY-002's RXE means regulators now consider "living longer" a testable, measurable, potentially labelable outcome.

Loyal's other program, LOY-001, targets IGF-1 in large breeds — Great Danes, Mastiffs, Bernese Mountain Dogs — the dogs that age catastrophically fast. LOY-001 received its RXE in 2023. Between the two programs, Loyal has the FDA on record twice acknowledging that lifespan extension is a legitimate pharmaceutical objective.

Meanwhile, the Dog Aging Project's TRIAD trial — Test of Rapamycin in Aging Dogs — received a $7 million NIH grant to expand enrollment from 170 to 580 dogs across 20+ sites. Previous DAP studies showed low-dose rapamycin improved cardiac function in aging dogs. Hearts stiffen with age. Rapamycin made them more compliant. The drug did in dogs' hearts what it was supposed to do in human biomarkers — except the dogs got the real dose.

TAME: The Trial That Might Outlive Its Participants

TAME — Targeting Aging with Metformin — launched with enormous ambition. Led by Dr. Nir Barzilai at Albert Einstein College of Medicine, it aims to enroll 3,000+ adults aged 65–79 across 14 sites to test whether a cheap, generic diabetes drug can delay the composite onset of cardiovascular disease, cancer, cognitive decline, and mortality.

If it works, TAME would establish aging itself as a treatable condition under FDA frameworks. That's not hyperbole. It's the explicit regulatory goal.

As of early 2026, the trial is still recruiting. No primary data has been published. The observational evidence that motivated it remains strong — diabetic patients on metformin appear to outlive matched non-diabetic controls in multiple cohort studies — but the prospective, randomized confirmation is years away.

The TAME trial's significance is less pharmacological than bureaucratic. Metformin activates AMPK, reduces inflammation, and mimics some effects of caloric restriction. These are real mechanisms. But the drug's main value to the field is regulatory: if TAME succeeds, the FDA would have a precedent for approving aging-indication drugs. Every other geroscience program is waiting in line behind this one trial.

The Senolytic Pivot

Unity Biotechnology raised $300 million to kill senescent cells. Their first systemic senolytic, UBX0101, failed in a Phase 2 knee osteoarthritis trial in 2020 and the stock cratered 60% in a day.

Then they pivoted to the eye.

UBX1325, published in NEJM Evidence, showed disease-modifying, long-lasting vision improvement in patients with diabetic macular edema. Not just symptom management — targeted clearance of senescent retinal cells producing durable structural change. The Phase 2b ASPIRE trial (NCT06011798) is now comparing UBX1325 against aflibercept, the standard of care.

Separately, the original senolytic cocktail — dasatinib plus quercetin (D+Q) — showed proof of concept in a Mayo Clinic pilot study of 14 patients with diabetic kidney disease. Senescent cells were measurably cleared. The sample was tiny, but the biology worked.

The pattern: senolytics haven't failed. Systemic senolytics — "clear all the zombie cells everywhere" — haven't yet demonstrated clinical benefit in humans. Targeted senolytics — "clear the zombie cells in this one organ" — are publishing in the New England Journal of Medicine.

What Actually Works So Far

Strip away the press releases and the pre-print hype. Here is what's survived contact with controlled data:

Rapamycin improves cardiac function in aging dogs. Multiple Dog Aging Project studies. Consistent direction. $7M NIH investment in expansion. The mechanism — mTOR inhibition mimicking caloric restriction — is among the most replicated in geroscience across yeast, worms, flies, and mice. It's the human dosing that remains unsolved.

IGF-1 reduction extends lifespan in large dogs. Loyal's LOY-001. FDA-acknowledged as a reasonable expectation of effectiveness for a lifespan label. The human analog — endocrine intervention to reduce growth signaling — is biologically plausible but ethically and practically complicated.

Targeted senolytic clearance produces durable organ-specific improvement. Unity's UBX1325 in diabetic macular edema. Published, peer-reviewed, advancing to Phase 2b. The retina may be the first organ where aging is treated as the mechanism, not just the backdrop.

Metformin might work, but we still don't know. Observational signal is persistent. Prospective trial is ongoing. The regulatory value exceeds the pharmacological value for the field as a whole.

The Measurement Wall

Every trial that tried to measure "aging" as a composite endpoint — PEARL, TAME in concept — has hit the same wall. Aging is not one thing. It's a thousand things happening on different schedules in different tissues. A biomarker panel that captures cardiac aging, immune aging, metabolic aging, and cognitive aging simultaneously doesn't exist. The trials that succeeded didn't try to measure everything. They picked one organ and one mechanism.

Dog hearts. Human retinas. Canine metabolism.

The field's billion-dollar lesson is about trial design, not biology. Rapamycin probably works. Senolytics clearly work in specific tissues. The drugs aren't the bottleneck. The endpoints are.

The Bottom Line

The first FDA-acknowledged lifespan extension drug will be a daily pill for senior dogs. Not because dogs are easier to treat — because they're easier to measure. A dog's lifespan is short enough to run a controlled trial in under a decade. A human's isn't. The field that promised to cure aging is learning that the hardest part isn't the biology. It's proving it worked.